Xisomab 3G3 for Lymphoma

Phase-Based Progress Estimates
Lymphoma+2 MoreXisomab 3G3 - Drug
All Sexes
What conditions do you have?

Study Summary

This trial studies xisomab 3G3 to see how well it works in preventing blood clots in cancer patients with catheters.

Eligible Conditions
  • Lymphoma
  • Multiple Myeloma
  • Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: From xisomab 3G3 infusion up to end of treatment visit (day 18)

Day 18
Time to clot symptoms
Time to detection of thrombosis
Day 60
Incidence of xisomab 3G3-associated adverse events (AEs)
Day 18
Incidence of catheter-associated thrombosis (CAT)
Proportion of patients that had a catheter occlusion requiring medical intervention
Quantification of coagulation measures: Activated partial thromboplastin time (aPTT)
Quantification of coagulation measures: Prothrombin time/international normalized ratio (PT/INR)
Quantification of coagulation measures: platelet count
Xisomab 3G3 pharmacokinetics

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

Supportive Care (xisomab 3G3)
1 of 1

Experimental Treatment

50 Total Participants · 1 Treatment Group

Primary Treatment: Xisomab 3G3 · No Placebo Group · Phase 2

Supportive Care (xisomab 3G3)
Experimental Group · 1 Intervention: Xisomab 3G3 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: from xisomab 3g3 infusion up to end of treatment visit (day 18)

Who is running the clinical trial?

National Heart, Lung, and Blood Institute (NHLBI)NIH
3,593 Previous Clinical Trials
46,945,796 Total Patients Enrolled
41 Trials studying Lymphoma
8,012 Patients Enrolled for Lymphoma
OHSU Knight Cancer InstituteLead Sponsor
209 Previous Clinical Trials
2,089,520 Total Patients Enrolled
18 Trials studying Lymphoma
1,031 Patients Enrolled for Lymphoma
Oregon Health and Science UniversityOTHER
895 Previous Clinical Trials
6,831,255 Total Patients Enrolled
6 Trials studying Lymphoma
415 Patients Enrolled for Lymphoma
Joseph Shatzel, M.D.Principal Investigator - OHSU Knight Cancer Institute
OHSU Knight Cancer Institute

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
In consultation with principal investigator (PI) and treating physician, participant's cancer-directed therapy allows for a 1-day period between administration of study drug and subsequent start of planned cancer-directed therapy.
You must provide written informed consent before any study-specific procedures or interventions are performed.
You are female and have not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) and are not postmenopausal.
You are scheduled to undergo insertion of a PICC line or indwelling central venous catheter as part of planned anticancer therapy per institutional standards.
You have a performance status of 0, 1, 2, or 3.